Industry
IND 2 Results LLC
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
Failure Rate
0.0%
0 terminated/withdrawn out of 3 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed trials have results
Key Signals
2 with results
Enrollment Performance
Analytics
Phase 3
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 3(2)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT02598596Phase 2Completed
Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect
Role: collaborator
NCT02578940Phase 3Completed
Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer
Role: collaborator
NCT02680041Phase 3Completed
18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment
Role: collaborator
All 3 trials loaded